CFS
MCID: CHR066
MIFTS: 67

Chronic Fatigue Syndrome (CFS)

Categories: Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 76 53 55 43 3 15 73
Myalgic Encephalomyelitis 12 76 53
Cfs 12 15
Chronic Fatigue Immune Dysfunction Syndrome 53
Systemic Exertion Intolerance Disease 53
Postviral Fatigue Syndrome 12
Encephalomyelitis, Myalgic 76
Fatigue Syndrome, Chronic 44
Myalgic Encephalitis 12
Chronic Fatigue 6

Classifications:



External Ids:

Disease Ontology 12 DOID:8544
ICD10 33 G93.3 R53.82
ICD9CM 35 780.71
MeSH 44 D015673
NCIt 50 C3037
SNOMED-CT 68 51771007 52702003
UMLS 73 C0015674

Summaries for Chronic Fatigue Syndrome

MedlinePlus : 43 What is chronic fatigue syndrome? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What causes chronic fatigue syndrome? Scientists don't know what causes CFS. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. Who is at risk for chronic fatigue syndrome? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What are the symptoms of chronic fatigue syndrome? CFS symptoms can include Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. How is chronic fatigue syndrome diagnosed? CFS can be difficult to diagnose. There are no tests for it, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including Asking about your health history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine or other tests What are the treatments for chronic fatigue syndrome? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems, and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to irritable bowel syndrome and brucellosis, and has symptoms including muscle weakness, fever and fatigue. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Sodium oxybate and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include testes, lymph node and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases : 53 Chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. It generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The main symptom is disabling fatigue that does not improve with rest. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. The exact cause is not known. There is still no cure or effective treatment for this condition but there are several clinical trials. There is debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome. There is no consensus on nomenclature or classification for these disorders. Different countries, organizations, and researchers continue to use different names to describe these conditions.

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Wikipedia : 76 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)
# Related Disease Score Top Affiliating Genes
1 irritable bowel syndrome 31.9 CRH IL10 SLC6A4 TNF
2 brucellosis 31.2 IL10 IL2 IL6 TNF
3 fibromyalgia 31.1 COMT CRH IGF1 IL6 SLC6A4
4 depression 30.6 CRH HTR1A MAOA NR3C1 SLC6A4 TPH2
5 personality disorder 30.4 COMT HTR1A MAOA SLC6A4
6 multiple sclerosis 30.3 IL10 IL1B IL2 IL6 TNF
7 lyme disease 30.2 IL1B IL6 TNF
8 alexithymia 30.2 COMT HTR1A SLC6A4
9 lung disease 30.0 IL10 IL1B IL6 TGFB1 TNF
10 anxiety 30.0 COMT CRH HTR1A MAOA NR3C1 SLC6A4
11 anorexia nervosa 29.9 COMT CRH IGF1 POMC SLC6A4
12 atypical depressive disorder 29.9 CRH MAOA SLC6A4
13 arthritis 29.9 IL10 IL1B IL6 TGFB1 TNF
14 q fever 29.8 IL10 IL1B IL6 TNF
15 viral infectious disease 29.8 EIF2AK2 IL10 IL1B IL2 IL6 RNASEL
16 chronic active epstein-barr virus infection 29.8 IL10 IL2 TGFB1
17 generalized anxiety disorder 29.7 COMT HTR1A MAOA SLC6A4
18 typhoid fever 29.7 IL1B IL6 TNF
19 arteries, anomalies of 29.7 IL1B IL6 TNF
20 juvenile rheumatoid arthritis 29.7 IL1B IL6 TNF
21 disease of mental health 29.7 COMT CRH HTR1A MAOA POMC SLC6A4
22 attention deficit-hyperactivity disorder 29.7 COMT HTR1A MAOA SLC6A4 TPH2
23 rheumatoid arthritis 29.6 IL10 IL1B IL2 IL6 TGFB1 TNF
24 spinal cord injury 29.6 IL6 TGFB1 TNF
25 paracoccidioidomycosis 29.6 IL10 IL2 IL6 TNF
26 colitis 29.6 IL10 IL1B IL2 IL6 TNF
27 chikungunya 29.6 IL1B IL6 TNF
28 autism 29.5 COMT HTR1A MAOA SLC6A4 TPH2
29 post-traumatic stress disorder 29.5 COMT CRH IL1B MAOA NR3C1 SLC6A4
30 sleep apnea 29.4 IGF1 IL1B IL6 TNF
31 borderline personality disorder 29.4 COMT HTR1A MAOA NR3C1 SLC6A4 TPH2
32 migraine with or without aura 1 29.4 COMT HTR1A MAOA SLC6A4 TNF
33 osteoarthritis 29.4 IL1B IL6 TGFB1 TNF
34 autoimmune disease 29.4 IL10 IL1B IL2 IL6 TNF
35 meningitis 29.4 IL10 IL1B IL6 TNF
36 ulcerative colitis 29.3 IL10 IL1B IL2 IL6 TNF
37 endogenous depression 29.2 CRH HTR1A IL1B IL2 MAOA NR3C1
38 bipolar disorder 29.1 COMT CRH HTR1A IGF1 MAOA NR3C1
39 inflammatory bowel disease 29.0 IL10 IL1B IL2 IL6 NR3C1 TGFB1
40 major depressive disorder 28.9 COMT CRH HTR1A IL1B IL6 MAOA
41 meconium ileus 11.5
42 cramp-fasciculation syndrome 11.4
43 postural orthostatic tachycardia syndrome 11.3
44 pain - chronic 11.3
45 persian gulf syndrome 11.3
46 young syndrome 11.2
47 shwachman-diamond syndrome 1 11.0
48 pseudohypoaldosteronism, type i, autosomal recessive 11.0
49 glucocorticoid resistance, generalized 11.0
50 alcohol sensitivity, acute 10.9

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


muscle weakness, fever, fatigue, pruritus, back pain, myalgia, sciatica, muscle rigidity, muscle cramp, muscle spasticity, (non-specific) malaise and fatigue, other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 EIF2AK2 IL10 IL1B IL2 PDCD2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 EIF2AK2 IL10 IL1B IL2 PDCD2 TGFB1
3 Decreased viability with paclitaxel GR00179-A-1 9.35 IGF1 IL10 TGFB1
4 Decreased viability with paclitaxel GR00179-A-2 9.35 IGF1
5 Decreased viability with paclitaxel GR00179-A-3 9.35 TGFB1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 COMT CRH HTR1A IL10 IL2 IL6
2 homeostasis/metabolism MP:0005376 10.43 COMT CRH HTR1A IGF1 IL10 IL1B
3 cardiovascular system MP:0005385 10.42 COMT HTR1A IGF1 IL10 IL1B IL2
4 growth/size/body region MP:0005378 10.39 CRH IGF1 IL10 IL1B IL2 IL6
5 cellular MP:0005384 10.35 CRH EIF2AK2 IGF1 IL10 IL2 IL6
6 hematopoietic system MP:0005397 10.35 COMT CRH EIF2AK2 IGF1 IL10 IL1B
7 endocrine/exocrine gland MP:0005379 10.34 COMT CRH IGF1 IL10 IL2 IL6
8 mortality/aging MP:0010768 10.33 EIF2AK2 HTR1A IGF1 IL10 IL1B IL2
9 immune system MP:0005387 10.32 COMT CRH EIF2AK2 IGF1 IL10 IL1B
10 integument MP:0010771 10.31 CRH IGF1 IL10 IL1B IL6 NR3C1
11 nervous system MP:0003631 10.27 COMT CRH HTR1A IGF1 IL10 IL1B
12 adipose tissue MP:0005375 10.19 CRH IGF1 IL6 NR3C1 POMC TGFB1
13 liver/biliary system MP:0005370 10.08 CRH IL10 IL2 IL6 NR3C1 POMC
14 neoplasm MP:0002006 10.06 EIF2AK2 IGF1 IL10 IL1B IL2 IL6
15 muscle MP:0005369 10.03 IGF1 IL10 IL6 NR3C1 SLC6A4 SUN2
16 no phenotypic analysis MP:0003012 9.92 CRH HTR1A IL10 IL2 NR3C1 POMC
17 reproductive system MP:0005389 9.81 COMT IGF1 IL10 IL2 IL6 NR3C1
18 renal/urinary system MP:0005367 9.8 COMT CRH IGF1 IL6 NR3C1 POMC
19 respiratory system MP:0005388 9.65 COMT CRH IGF1 IL10 IL2 IL6
20 skeleton MP:0005390 9.28 CRH IGF1 IL10 IL1B IL6 NR3C1

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium oxybate Approved Phase 4 502-85-2 5360545
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
4
Iron Approved Phase 4 7439-89-6 23925
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6 tannic acid Approved Phase 4
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
9
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
10 Anesthetics, Intravenous Phase 4
11 Anesthetics Phase 4,Phase 1
12 Central Nervous System Depressants Phase 4,Not Applicable
13 Adjuvants, Anesthesia Phase 4,Phase 1
14 Anesthetics, General Phase 4
15 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
16 Ergocalciferols Phase 4
17 Vitamin D2 Phase 4
18 Bone Density Conservation Agents Phase 4
19 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
20 Calciferol Phase 4
21 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
22 Dopamine Uptake Inhibitors Phase 4,Phase 2
23 Dopamine Agents Phase 4,Phase 2,Phase 3
24 Central Nervous System Stimulants Phase 4,Phase 2
25 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
27 Lisdexamfetamine Dimesylate Phase 4
28 Phosphodiesterase 5 Inhibitors Phase 4
29 Sildenafil Citrate Phase 4 171599-83-0
30 Citrate Phase 4
31 Phosphodiesterase Inhibitors Phase 4
32 Vasodilator Agents Phase 4,Phase 1
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
34 Ferric Compounds Phase 4
35 Hematinics Phase 4
36
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
37
Norepinephrine Approved Phase 2, Phase 3,Phase 3,Not Applicable 51-41-2 439260
38
Serine Approved, Nutraceutical Phase 2, Phase 3,Not Applicable 56-45-1 5951
39
Vitamin C Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Not Applicable 50-81-7 5785 54670067
40
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Not Applicable 303-98-0 5281915
41 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
42 Antibodies Phase 3,Phase 2,Phase 1
43 Antirheumatic Agents Phase 3,Phase 2
44 Immunoglobulins Phase 3,Phase 2,Phase 1
45 Anti-Infective Agents Phase 3,Phase 1,Phase 2
46 Antiviral Agents Phase 3,Phase 1,Phase 2
47 Psychotropic Drugs Phase 2, Phase 3,Phase 3,Not Applicable
48 Antidepressive Agents Phase 2, Phase 3,Phase 3,Not Applicable
49 Antioxidants Phase 2, Phase 3,Not Applicable
50 Protective Agents Phase 2, Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
5 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
6 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
7 Giardia Induced Fatigue and Functional Gastrointestinal Diseases Completed NCT00860236 Phase 4
8 A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
9 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
10 B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. Unknown status NCT02229942 Phase 3 Rituximab;Placebo
11 Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS. Unknown status NCT01907711 Phase 2, Phase 3
12 Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise Unknown status NCT01689467 Phase 2, Phase 3
13 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
14 Drug Intervention in Chronic Fatigue Syndrome Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
15 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Completed NCT00215800 Phase 3 Ampligen
16 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
17 Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
18 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
19 Exercise and Behavioral Therapy Trial (EBT). Completed NCT00007748 Phase 3
20 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
21 The Exercise Response to Pharmacologic Cholinergic Stimulation in Preload Failure Not yet recruiting NCT03674541 Phase 3 Pyridostigmine
22 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
23 High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Unknown status NCT02924831 Phase 2
24 The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
25 Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)
26 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) Unknown status NCT02444091 Phase 2 Cyclophosphamide
27 Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) Unknown status NCT00478465 Phase 1, Phase 2 valganciclovir
28 Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Completed NCT00540254 Phase 1, Phase 2
29 Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Completed NCT01512342 Phase 2
30 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Completed NCT01156909 Phase 2 Rituximab
31 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Completed NCT01040429 Phase 2 Clonidine;Lactose capsula
32 Acupressure for Post-Treatment Cancer Fatigue Completed NCT00959998 Phase 2
33 Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain Completed NCT00524420 Phase 2
34 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI) Completed NCT00810368 Phase 2 Carnosine;Placebo
35 Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Recruiting NCT03613129 Phase 1, Phase 2 CT38
36 Creatine Supplementation in Chronic Fatigue Syndrome Active, not recruiting NCT02374112 Phase 2
37 The Comeback Study Not yet recruiting NCT03691987 Phase 2
38 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Terminated NCT01730495 Phase 2 Etanercept
39 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Terminated NCT01156922 Phase 2 Rituximab
40 Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
41 Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01471652 Phase 2 Nutraceutical supplements;Placebo
42 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
43 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects Completed NCT02955420 Phase 1 BC 007;NaCl 0.9 %
44 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Active, not recruiting NCT02854683 Phase 1 Normal Saline
45 Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. Not yet recruiting NCT03807973 Phase 1
46 Assessment of Neuroinflammation in Central Inflammatory Disorders Using [18F]DPA-714. Not yet recruiting NCT03759522 Phase 1 DPA-714 PET/MRI
47 Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome Unknown status NCT01893619
48 Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome Unknown status NCT01534130 Not Applicable
49 Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial Unknown status NCT02964533 Not Applicable
50 Use of a Monitor in ME/CFS Unknown status NCT01908036

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

41
Testes, Lymph Node, Heart, Brain, Pituitary, Prostate, B Cells

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 1584)
# Title Authors Year
1
Does fatigue and distress in a clinical cohort of adolescents with chronic fatigue syndrome correlate with fatigue and distress in their parents? ( 30342433 )
2019
2
Chronic fatigue syndrome (CFS): Suggestions for a nutritional treatment in the therapeutic approach. ( 30551349 )
2019
3
Operationalizing Substantial Reduction in Functioning Among Young Adults with Chronic Fatigue Syndrome. ( 29872989 )
2018
4
Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics. ( 29968805 )
2018
5
The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. ( 29759891 )
2018
6
Poor self-reported sleep quality and health-related quality of life in patients with chronic fatigue syndrome/myalgic encephalomyelitis. ( 29770505 )
2018
7
Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. ( 29409505 )
2018
8
Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. ( 29969498 )
2018
9
Rethinking childhood adversity in chronic fatigue syndrome. ( 29392095 )
2018
10
Hair and salivary cortisol in a cohort of women with chronic fatigue syndrome. ( 29807037 )
2018
11
Efficacy of web-based cognitive-behavioural therapy for chronic fatigue syndrome: randomised controlled trial. ( 29436329 )
2018
12
The etiologic relation between disequilibrium and orthostatic intolerance in patients with myalgic encephalomyelitis (chronic fatigue syndrome). ( 29588088 )
2018
13
A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications. ( 29411266 )
2018
14
Cardiovascular characteristics of chronic fatigue syndrome. ( 29399336 )
2018
15
Severe eosinophilic colitis caused by neuropathic agents in a patient with chronic fatigue syndrome and functional abdominal pain: case report and review of the literature. ( 29890559 )
2018
16
Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). ( 29867995 )
2018
17
Glucocorticoid receptor DNA methylation and childhood trauma in chronic fatigue syndrome patients. ( 29275786 )
2018
18
Cerebral blood flow and heart rate variability predict fatigue severity in patients with chronic fatigue syndrome. ( 29855991 )
2018
19
Deconstructing post-exertional malaise in myalgic encephalomyelitis/ chronic fatigue syndrome: A patient-centered, cross-sectional survey. ( 29856774 )
2018
20
Effects of a short-term aquatic exercise intervention on symptoms and exercise capacity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis: a pilot study. ( 29923110 )
2018
21
Structural brain changes versus self-report: machine-learning classification of chronic fatigue syndrome patients. ( 29846797 )
2018
22
Cortical hypoactivation during resting EEG suggests central nervous system pathology in patients with chronic fatigue syndrome. ( 29802861 )
2018
23
A reboot for chronic fatigue syndrome research. ( 29300036 )
2018
24
Chronic fatigue syndrome (CFS/ME) symptom-based phenotypes and 1-year treatment outcomes in two clinical cohorts of adult patients in the UK and The Netherlands. ( 29275782 )
2018
25
Chronic fatigue syndrome in Chinese middle-school students. ( 29369204 )
2018
26
Value of Circulating Cytokine Profiling During Submaximal Exercise Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 29426834 )
2018
27
Dutch Health Council Advisory Report on Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: Taking the Wrong Turn. ( 29772739 )
2018
28
Correction: Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. ( 29420633 )
2018
29
Circadian rhythm abnormalities and autonomic dysfunction in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. ( 29874259 )
2018
30
Myalgic encephalomyelitis/chronic fatigue syndrome and the biopsychosocial model: a review of patient harm and distress in the medical encounter. ( 29929450 )
2018
31
Recent insights into 3 underrecognized conditions: Myalgic encephalomyelitis-chronic fatigue syndrome, fibromyalgia, and environmental sensitivities-multiple chemical sensitivity. ( 29898928 )
2018
32
Eukaryotes in the gut microbiota in myalgic encephalomyelitis/chronic fatigue syndrome. ( 29375937 )
2018
33
Improvement of severe myalgic encephalomyelitis/chronic fatigue syndrome symptoms following surgical treatment of cervical spinal stenosis. ( 29391028 )
2018
34
Cerebral Blood Flow and Heart Rate Variability in Chronic Fatigue Syndrome: A Randomized Cross-Over Study. ( 29357332 )
2018
35
Patients with chronic fatigue syndrome do not score higher on the autism-spectrum quotient than healthy controls: Comparison with autism spectrum disorder. ( 29738079 )
2018
36
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease. ( 29635081 )
2018
37
Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. ( 29587879 )
2018
38
Graded exercise self-help for chronic fatigue syndrome in GETSET. ( 29595490 )
2018
39
Graded exercise self-help for chronic fatigue syndrome in GETSET. ( 29595491 )
2018
40
Graded exercise self-help for chronic fatigue syndrome in GETSET. ( 29595492 )
2018
41
Graded exercise self-help for chronic fatigue syndrome in GETSET. ( 29595493 )
2018
42
Graded exercise self-help for chronic fatigue syndrome in GETSET. ( 29595494 )
2018
43
Graded exercise self-help for chronic fatigue syndrome in GETSET - Authors' reply. ( 29595495 )
2018
44
Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial. ( 29602463 )
2018
45
'It's like being a slave to your own body in a way': a qualitative study of adolescents with chronic fatigue syndrome. ( 29607759 )
2018
46
Higher Prevalence of "Low T3 Syndrome" in Patients With Chronic Fatigue Syndrome: A Case-Control Study. ( 29615976 )
2018
47
Lower regulatory frequency for postural control in patients with fibromyalgia and chronic fatigue syndrome. ( 29617424 )
2018
48
Systemic exertion intolerance disease/chronic fatigue syndrome is common in sleep centre patients with hypersomnolence: A retrospective pilot study. ( 29624767 )
2018
49
Fatigue Is Associated With Altered Monitoring and Preparation of Physical Effort in Patients With Chronic Fatigue Syndrome. ( 29628071 )
2018
50
Systemic exertion intolerance disease diagnostic criteria applied on an adolescent chronic fatigue syndrome cohort: evaluation of subgroup differences and prognostic utility. ( 29637195 )
2018

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh37 Chromosome MT, 9355: 9355
2 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh38 Chromosome MT, 9355: 9355

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 EIF2AK2 IGF1 IL10 IL1B IL2 IL6
2
Show member pathways
13.37 EIF2AK2 IL10 IL1B IL2 IL6 MAOA
3
Show member pathways
13.33 IGF1 IL10 IL1B IL2 IL6 TGFB1
4
Show member pathways
13.06 IL10 IL1B IL2 IL6 RNASEL TGFB1
5
Show member pathways
12.92 IL10 IL1B IL2 IL6 TGFB1 TNF
6
Show member pathways
12.85 EIF2AK2 IL1B IL2 IL6 RNASEL TNF
7
Show member pathways
12.76 EIF2AK2 IGF1 IL1B IL2 IL6 TGFB1
8
Show member pathways
12.65 IL10 IL1B IL2 IL6 TGFB1 TNF
9
Show member pathways
12.64 EIF2AK2 IL10 IL1B IL2 IL6 TNF
10 12.61 IL10 IL1B IL2 RNASEL TNF
11
Show member pathways
12.49 IL10 IL1B IL2 IL6 TGFB1 TNF
12 12.43 IL2 IL6 TGFB1 TNF
13
Show member pathways
12.36 IL1B IL2 IL6 TNF
15 12.3 IL10 IL1B IL6 TGFB1 TNF
16
Show member pathways
12.29 IL10 IL1B TGFB1 TNF
17
Show member pathways
12.28 IL10 IL1B IL2 IL6 TNF
18
Show member pathways
12.25 IGF1 IL6 TGFB1 TNF
19
Show member pathways
12.18 IGF1 IL10 IL1B IL2 IL6 RNASEL
20
Show member pathways
12.14 IGF1 IL10 IL6 TGFB1
21 12.13 IGF1 IL6 NR3C1 TGFB1 TNF
22
Show member pathways
12.09 EIF2AK2 IGF1 IL10 IL1B IL2 IL6
23 12.08 IL1B IL2 IL6 TGFB1 TNF
24
Show member pathways
12.07 IL10 IL1B IL2 IL6 TGFB1 TNF
25 12.06 IL10 IL2 IL6 TNF
26 12.05 HTR1A MAOA SLC6A4 TPH2
27 12.01 IGF1 IL1B IL6 RNASEL TGFB1
28 11.98 IL1B IL6 TGFB1 TNF
29 11.95 CRH IL2 POMC TGFB1
30 11.93 IL10 IL1B IL6 TGFB1 TNF
31 11.92 IL1B IL6 TGFB1 TNF
32 11.88 IL2 IL6 NR3C1 POMC
33 11.86 IL10 IL1B IL2 TNF
34 11.86 IL10 IL1B IL6 MAOA POMC TGFB1
35 11.84 IL10 IL1B IL6 TNF
36 11.71 IGF1 IL1B IL6 TGFB1 TNF
37
Show member pathways
11.69 IL1B IL2 IL6 NR3C1 TNF
38 11.67 IL10 IL1B IL2 IL6 TGFB1 TNF
39 11.63 IL1B IL6 TNF
40 11.61 IL10 IL1B IL6 TNF
41 11.6 IL1B IL2 TGFB1 TNF
42 11.59 IL2 IL6 TNF
43 11.56 IGF1 IL6 TGFB1
44 11.55 IGF1 IL10 IL1B IL2 IL6 TGFB1
45 11.54 IL10 IL1B IL6 TGFB1 TNF
46 11.53 IGF1 IL10 TGFB1
47 11.49 HTR1A IL10 IL1B IL6 MAOA NR3C1
48 11.48 IGF1 IL1B IL6 NR3C1 TNF
49
Show member pathways
11.44 IL1B MAOA SLC6A4 TNF TPH2
50 11.42 IL10 IL1B IL6 TNF

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CRH IGF1 IL10 IL1B IL2 IL6
2 extracellular space GO:0005615 9.28 CRH IGF1 IL10 IL1B IL2 IL6

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.97 IL10 IL1B IL6 TNF
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 IGF1 IL10 IL1B IL2 IL6 NR3C1
3 positive regulation of gene expression GO:0010628 9.95 CRH IGF1 IL1B IL6 SLC6A4 TGFB1
4 response to drug GO:0042493 9.93 COMT CRH IL10 IL1B SLC6A4 TGFB1
5 positive regulation of protein phosphorylation GO:0001934 9.91 CRH IL1B IL2 TGFB1 TNF
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.9 IGF1 IL6 TGFB1
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 IL6 TGFB1 TNF
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 IL10 IL1B IL6 TNF
9 cellular response to organic cyclic compound GO:0071407 9.88 IL1B TGFB1 TNF
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IGF1 IL2 IL6
11 response to estrogen GO:0043627 9.88 COMT CRH TPH2
12 positive regulation of T cell proliferation GO:0042102 9.86 IL1B IL2 IL6
13 positive regulation of interleukin-6 production GO:0032755 9.86 IL1B IL6 TNF
14 response to organic substance GO:0010033 9.86 IL10 SLC6A4 TGFB1 TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 IGF1 IL6 TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 EIF2AK2 IL1B TNF
17 negative regulation of fat cell differentiation GO:0045599 9.84 IL6 TGFB1 TNF
18 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.84 IGF1 IL10 TNF
19 positive regulation of interferon-gamma production GO:0032729 9.83 IL1B IL2 TNF
20 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 EIF2AK2 IL1B IL6 TGFB1 TNF
21 negative regulation of viral genome replication GO:0045071 9.81 EIF2AK2 RNASEL TNF
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 IL1B TGFB1 TNF
23 negative regulation of mitotic cell cycle GO:0045930 9.8 IL10 TGFB1 TNF
24 cellular response to dexamethasone stimulus GO:0071549 9.78 CRH NR3C1 TGFB1
25 negative regulation of neurogenesis GO:0050768 9.75 IL1B IL6 TNF
26 response to immobilization stress GO:0035902 9.74 CRH IL1B TGFB1
27 positive regulation of interleukin-17 production GO:0032740 9.73 IL2 TGFB1
28 cell activation GO:0001775 9.73 IGF1 TGFB1
29 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL2 IL6
30 positive regulation of regulatory T cell differentiation GO:0045591 9.72 IL2 TGFB1
31 positive regulation of chemokine production GO:0032722 9.72 EIF2AK2 IL6 TNF
32 catecholamine metabolic process GO:0006584 9.71 COMT MAOA
33 neurotransmitter catabolic process GO:0042135 9.71 COMT MAOA
34 negative regulation of lipid storage GO:0010888 9.71 IL6 TNF
35 dopamine catabolic process GO:0042420 9.7 COMT MAOA
36 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
37 positive regulation of glial cell proliferation GO:0060252 9.7 IL1B IL6 TNF
38 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IL1B TNF
39 regulation of establishment of endothelial barrier GO:1903140 9.68 IL1B TNF
40 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 IL1B TNF
42 protein kinase B signaling GO:0043491 9.67 IGF1 IL1B TGFB1 TNF
43 positive regulation of fever generation GO:0031622 9.66 IL1B TNF
44 chronic inflammatory response to antigenic stimulus GO:0002439 9.65 IL1B TNF
45 sequestering of triglyceride GO:0030730 9.64 IL1B TNF
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 IL1B TNF
47 positive regulation of mononuclear cell migration GO:0071677 9.62 TGFB1 TNF
48 receptor biosynthetic process GO:0032800 9.61 IL10 TNF
49 regulation of hematopoietic progenitor cell differentiation GO:1901532 9.59 EIF2AK2 PDCD2
50 regulation of serotonin secretion GO:0014062 9.58 CRH HTR1A

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IGF1 IL10 IL2 IL6 TGFB1
2 serotonin binding GO:0051378 9.16 HTR1A SLC6A4
3 cytokine activity GO:0005125 9.1 IL10 IL1B IL2 IL6 TGFB1 TNF

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....